The immune environment and the potential for neuroendocrine tumors (NETs) to respond to immune checkpoint inhibitors remain largely unexplored. We assessed immune checkpoint marker expression, lymphocytic infiltrate, and associated mutational profiles in a cohort of small intestine and pancreatic NETs.
T reatment options for patients with advanced, well-differentiated neuroendocrine tumors (NETs) remain limited. Currently approved systemic treatments in this setting include somatostatin analogs, everolimus, and sunitinib; however, tumor regression with these agents is rare. [1] [2] [3] [4] Treatment with immune checkpoint inhibitors targeting PD-L1 or PD-1 has led to significant tumor responses in a broad range of human malignancies. 5 The potential for NETs to respond to immune checkpoint inhibition remains uncertain.
Response to treatment with checkpoint inhibitors has been associated with immunohistochemical expression of PD-1 and its ligand PD-L1, although clinical benefit and responses have been observed even in the absence of expression. 6 PD-L2, such as PD-L1, has been shown to inhibit T-cell proliferation and T-cell-mediated killing. 7 Though less well studied than PD-L1, PD-L2 expression has also been associated with response to checkpoint inhibition in some settings, including head and neck cancer and melanoma. [8] [9] [10] The degree of T-cell infiltration of tumors has also been considered as both a general prognostic factor and as a specific predictor of response to checkpoint inhibition. Tumor infiltration with effector (ie, CD3/CD8 positive) T-cells and CD45RO positive T-cells, indicative of T-cell exposure to tumor antigen, have been associated with improved host immune response and improved overall survival in colorectal cancer, 11 whereas expression of FOXP3 (Treg) cells has been associated with the presence of an immunosuppressive immune environment. [12] [13] [14] Similar findings, showing improved survival associated with high CD8 infiltrates and poor survival with increased FOXP3 (Treg) infiltrates, were observed in a study of clear cell renal cell carcinoma. 15 The presence of CD8 positive T-cell infiltrates has been associated with improved response to checkpoint inhibitors in patients with melanoma. 16 Both host immune response and response to checkpoint inhibition have, in turn, been associated with mutational burden. The presence of microsatellite instability has been associated with both the presence of a robust immune infiltrate as well as response to checkpoint inhibition across a range of human malignancies, and the PD-1 inhibitor pembrolizumab was recently approved for this indication. 17, 18 Mutational burden in the absence of microsatellite instability has also been shown to predict a favorable response to PD-1 or PD-L1 blockade. 19 Checkpoint marker expression and host immune response in NETs remain relatively unexplored. Small cell carcinoma, considered to be the most aggressive NETs subtype, has been shown to express both PD-1 and PD-L1, and the PD-1 inhibitor, Nivolumab, either alone or in combination with Ipilimumab has shown activity in this setting. 20 In contrast, few studies have explored expression of immune checkpoint markers in more common, well-differentiated NETs. Expression of both PD-1 and PD-L1 was reported in one study of well-differentiated pulmonary NETs, whereas expression of these markers was not identified NETs of the foregut or hindgut. [21] [22] [23] No studies to date have correlated checkpoint marker expression, immune infiltrates, and mutational burden in NETs.
To better characterize both checkpoint marker expression and the more general immune environment of NETs, we examined the expression of the key checkpoint protein PD-1, PD-L1, and PD-L2 on both tumor and surrounding stromal cells in cohorts of small intestine NETs (SINETs) and pancreatic NETs (pNETs). We further evaluated T-cell lymphocytic infiltrates and mutational profiles in the tumor specimens and assessed associations between immune checkpoint marker expression, T-cell infiltrates, and tumoral mutational profiles.
MATERIALS AND METHODS

Study Population
Archival NET tumor specimens with associated demographic and clinical information were obtained from the Dana-Farber Cancer Institute Neuroendocrine Tumor Biospecimen database at Dana-Farber Cancer Institute, under an institutional review board-approved study.
Assessment of Immune Checkpoint Markers and Lymphocytic Infiltrate by Immunohistochemistry
Immunostaining for PD-1 (EH33), PD-L1 (405.9A11), and PD-L2 (366C.9E5) was performed using an automated staining system (BOND III Fully Automated Immunohistochemistry [IHC] and ISH; Leica Biosystems, Buffalo Grove, Ill) following the manufacturer's protocol. Four-micrometer paraffin-embedded sections were prebaked at 60°C for 1 hour. Slides were then loaded onto Bond III with "Bond Universal Covertiles" (Leica Biosystems). PD-1 (EH33) immunostaining was performed with 1:1000 dilution using Da Vinci Green Diluent (Biocare Medical, Pacheco, Calif ). PD-L1 (405.9A11) immunostaining was performed with 1:100 dilution (final concentration: 13 μg/mL) using Ab Discovery Diluent (Ventana Medical Systems, Oro Valley, Ariz). PD-L2 (366C.9E5) staining used the same reagents. Slides were first dewaxed and rehydrated. Heat-induced antigen retrieval was performed using ER2 solution (pH 8) (Leica Biosystems) for 20 minutes (PD-1) and 30 minutes (PD-L1, PD-L2). For PD-1, the primary antibody was incubated for 30 minutes, followed by 10 minutes of postprimary blocking reagent, 10 minutes of horseradish peroxidaselabeled polymer, 5 minutes of peroxidase block, and 10 minutes of DAB developing. For PD-L1 and PD-L2, the primary antibody was incubated for total of 2 hours with 2 separate applications, followed by 8 minutes of postprimary blocking reagent, 12 minutes of horseradish peroxidase-labeled polymer, 5 minutes of peroxidase block, and 15 minutes of DAB developing. Slides were counterstained by hematoxylin for 5 minutes. Tonsil sections were used as positive controls for PD-1, PD-L1, and PD-L2.
Two pathologists A.D.S. and Y.M. analyzed and scored each tumor independently, using an Olympus (Tokyo, Japan) microscope model BX43. Tumoral membranous expression of PD-L1 and PD-L2 was recorded as absent if less than 5% of cells had any intensity of membrane staining and positive if 5% or more of cells had any intensity of membrane staining. 24 PD-L1 and PD-L2 cytoplasmic expression in neoplastic cells was reported using a score ranging from 0 to 3 (0-absent, <10% with any intensity; 1-weak, ≥10%; 2-moderate, ≥10% with moderate intensity; 3-strong, ≥10% with strong intensity). 24 For the analysis of stromal cells, positive PD-1, PD-L1, or PD-L2 cells were counted in 10 hpf (microscopic high power field) per section and the absolute number was recorded. The average of the number of positive cells per high power field was used to create scores as follows: 0 (absence of positive cells), 1 (1-20 cells/hpf), 2 (20-50 cells/hpf), and 3 (>50 cells/hpf). 24 
Immunohistochemical Analysis of T-Cell Infiltrates
Immunostaining was performed for CD3 (clone 7.2.38, 1:250; Dako Cytomation, Carpinteria, Calif ), CD8 (clone C8/144B, 1:100; Dako Cytomation), CD45RO (clone UCHL1, 1:100; Dako Cytomation), and FOXP3 (clone 206D, 1:50; BioLegend, San Diego, Calif). Antigen retrieval was performed in deparaffinized 4-μm thick tissue sections in EDTA solution (pH 8.0) (Abcam, Cambridge, Mass) and slides were microwaved for 15 minutes for the markers CD3, CD8, and FOXP3. For CD45RO, citrate buffer (pH 6.0) (BioScience, San Jose, Calif ) was used for antigen retrieval and slides were microwaved for 17 minutes. Sections were treated by endogenous peroxidase blocker (10 minutes) and protein blocker (20 minutes) and then incubated for 1 hour at room temperature with primary mouse monoclonal antibodies. Envision System horseradish peroxidase-labeled polymer antimouse (Dako Cytomation, Glostrup, Demark) was then applied for 30 minutes, followed by visualization using the chromogen 3,3-diaminobenzidine (Dako) and hematoxylin counterstain.
One pathologist (A.D.S.) initially analyzed and scored the T-cell infiltrates using an Olympus microscope model BX43. The location of the lymphocytes was defined as intratumoral (lymphocytes present on top of neoplastic cells, between neoplastic cells and within the stroma immediately surrounding the neoplastic cells) or extratumoral (lymphocytes present at the edge of the tumor or at the interface between normal tissue and the tumor edge or capsule). Sections of each tumor were divided in 4 equal sized areas and the absolute number of lymphocytes was manually counted in at least 2 hpf in each quarter. Areas with highest density of lymphoid cells were prioritized; though we also considered at least two random areas in the center of the tumor, counting 10 hpf per section, for each T-cell category. Intravascular lymphocytes were excluded, as were necrotic, ulcerated, or heavily hemorrhagic areas. The average of the number of T-cells per high power field was used to create scores as follows: 0 (absence of positive cells), 1 (1-20 cells/hpf), 2 (20-50 cells/hpf), and 3 (>50 cells/hpf ). Cases were categorized as having either low (scores 0 and 1) or high density (scores 2 and 3) lymphocytic zinfiltrates. 11, 24, 25 A random sample of 45 cases was analyzed by a second pathologist Y.M. to ensure agreement in scores. We confirmed interobserver agreement, with a weighted κ value of 0.68 for CD45RO, 0.72 for CD3, 0.78 for CD8, and 0.66 for FOXP3.
RNA Sequencing
RNA sequencing was used to further characterize the relative expression of PD-L1 and PD-L2 in snap frozen tissue. A small portion from each primary tumor (6 pNETs, 23 SINETs) was pulverized using the Covaris (Worburn, Mass) T-prep method on dry ice (cat# 520097). The Agencourt RNAdvance (Agencourt Bioscience Corporation, A Beckman Coulter Company, Beverly, Mass) for isolation of nucleic acids from frozen tissue (cat# A32645) was implemented on a Biomek FXP Laboratory Automation Workstation (Beckman Coulter Life Sciences, Indianapolis, Ind) (dualarm system with multichannel pipette and span-8 pipetters, cat# A31844). Briefly, the tissue is lysed, after which the RNA is immobilized onto the magnetic particles. The RNA is then treated with DNase and the contaminants rinsed away using a simple wash procedure. RNA isolates were eluted in a 55-uL volume of RNase/DNase-free H 2 O. All RNA was stored at −80°C. RNA quality was assessed by Agilent (Santa Clara, Calif ) Bioanalyzer using the RNA 6000 pico kit (cat# 5067-1513). A total of 150 ng RNA was used as input for RNA-Seq library preparation. Removal of ribosomal RNA (rRNA) and human mitochondrial RNA was performed using biotinylated, target-specific oligos combined with Ribo-Zero Gold rRNA removal beads from the TruSeq Stranded Total RNA kit (cat# RS-122-2301; Illumina, San Diego, Calif ). The method was automated on the Biomek FXP Laboratory Automation Workstation. The Stranded TruSeq method comprised rRNA removal, cDNA synthesis and purification, and PCR amplification. cDNA libraries were quantified using the Quanti-iT PicoGreen assay (cat# P7589; Life Technologies, Carlsbad, Calif ). A total of 1 μL of cDNA was required for quantification. Concentration is measured as nanogram per microliter. Libraries were excited at 480 nm, and the fluorescence emission intensity was measured at 520 nm using a Victor X3 spectrophotometer (cat# 2030-0030; Perkin Elmer, Waltham, Mass). Fluorescence intensity was plotted versus concentration over the low calibration range (0-50 ng/μL). Libraries were also quality checked by Agilent Bioanalyzer using the high-sensitivity DNA kit (cat# 5067-4626). cDNA libraries were then sequenced on the Illumina NextSeq500 platform as 75 bp paired end reads. Data were streamed in real time to the Illumina BaseSpace cloud tool. TopHat Alignment (Version: 1.0.0 using TopHat2 alignment) was used to align the data to the genome, Homo sapiens UCSC hg19 (RefSeq gene annotations). FPKM abundance estimates of reference genes and transcripts were produced. Mean FPKM abundance of PD-L1 and PD-L2 was calculated.
DNA Sequencing and Analysis
Assessment of mutational status in SINET has been previously described; data from this study were applied to the cohort of SINETused in this study. 26 For assessment of pNET mutational status, 200 ng of gDNA from 27 tumor specimens was submitted for mutational profiling, together with matched normal tissue from adjacent pancreas or from blood specimens derived from the same patient. Mutational status was assessed using OncoPanel v3.0, which is a custom hybrid capture bait set (Agilent Technologies, Inc), created by the Center for Cancer Genome Discovery at the DanaFarber Cancer Institute, covering the exons of 560 genes of known cancer relevance, including MEN1, DAXX, ATRX, and selected mTOR pathway genes. Sequencing libraries were prepared as previously described, 27 with inclusion of a unique barcode for each sample to enable pooling. Libraries were quantified using a MiSeq Nano flow cell (Illumina, Inc), pooled in equal mass to 500 ng total, and captured using the OncoPanel_v3.0 using the Agilent SureSelect hybrid capture kit (Agilent Technologies, Inc). Captured libraries were quantitated using qPCR (Kapa Biosystems, Inc, Wilmington, Mass), further pooled, and sequenced on 2 lanes of an Illumina HiSeq3000. Pooled sample reads were deconvoluted and sorted using the Picard tools (http://broadinstitute.github.io/picard/picardmetric-definitions.html for details). The reads were aligned to the reference sequence b37 edition from the Human Genome Reference Consortium using bwa (http://bio-bwa.sourceforge.net/bwa.shtml) using the following parameters: "-q 5 -l 32 -k 2 -o 1," and duplicate reads were identified and removed using the Picard tools. 28 The alignments were further refined using the GATK tool for localized realignment around indel sites: (http://gatkforums.broadinstitute. org/discussion/38/local-realignment-around-indels). Recalibration of the quality scores was also performed using GATK tools: (http:// gatkforums.broadinstitute.org/discussion/44/base-quality-scorerecalibration-bqsr).
The average mean target coverage was Â165 for samples reaching 80% of target bases covered Â30 or greater. The samples having less than 80% of the targets covered Â30 were excluded from the analysis. Mutation analysis for single nucleotide variants (SNVs) was performed using MuTect v1.1.4 29 in paired mode by pairing the tumor to a matched normal or to Centre d'Etude du Polymorphism Humain control DNA if no matched normal was available (n = 4) and annotated using variant effect predictor, 30 and the SomaticIndelDetector tool that is part of the GATK was used for indel calling. For tumors without a matching normal, variants were filtered against the 6500 exome release of the Exome Sequencing Project database. Variants represented at more than 1% in either the African American or European-American populations and not in COSMIC of greater than Â2 were considered to be likely germline.
Statistical Analysis
SAS software (Version 9.2; SAS Institute Inc, Cary, NC) was used. All P values were two-sided at an α level of 0.05. We used the χ 2 test or Fisher's exact test when applicable, to detect differences in the frequencies of the categorized expression levels among the tumor subgroups. Cox proportional hazards regression models were used to compute event hazard ratio and 95% confidence interval. Multivariate Cox proportional hazards regression models included sex, age at diagnosis, tumor/node/metastasis stage (M0 vs M1), and MKi-67 labeling index. For RNA-seq data, the mean and standard deviation were calculated in Excel (Microsoft, Redmond, Wash).
RESULTS
Clinicopathological Characteristics of SINET and pNET
We evaluated tumors from 95 patients comprising 64 SINETs and 31 pNETs ( Table 1 ). All cases had well-differentiated histology, and the majority (91/95) were classified as grade 1 or 2 based on the World Health Organization classification. 31 Four pNETs were classified as having well-differentiated grade 3 tumors based on a proliferative index (MKI-67) of more than 20%. 32 Nearly all tumors evaluated were primary tumors; in 4 cases (2 pNETs and 2 SINETs), tumor samples were derived from metastatic lesions.
Expression of PD-1, PD-L1, and PD-L2 in NET
Tumoral expression of PD-L1 was observed in no cases of SINETs and in only 7.4% of pNETs (Fig. 1, Table 2 ). PD-1 expression, limited to the stromal compartment, was also uncommon and was observed at a high level in only a single case of SINET. In contrast, strong expression of PD-L2 was observed in a high proportion of NET cells in both the small intestine (82%) and pancreas (97%). Notably, tumoral expression of PD-L2 was in most cases limited to the cytoplasm rather than the membrane. Strong expression of PD-L2 in the stromal compartment was not observed.
To validate these observations, we assessed relative PD-L1 and PD-L2 expression in an independent cohort of fresh frozen tissue samples comprising 6 pNETs and 23 SINETs. Consistent with our IHC results, mRNA expression of PD-L2 was higher than mRNA expression of PD-L1 in both tumor types (Fig. 2) .
T-cell Immune Infiltrates in SINET and pNET
We next evaluated T-cell infiltrates in both the intratumoral and extratumoral compartments with a panel of T-cell markers comprising CD3 (general T-cell marker), CD45RO (T memory), CD8 (cytotoxic T-cell), and FOXP3 (T regulatory cell) ( Table 3 , Fig. 3 ). CD45RO, CD3, and CD8 T-cell infiltrates in the intratumoral compartment were relatively similar between SINET and pNET: across the 3 populations, 32% to 65% of pNETs and 14% to 48% of SINETs demonstrated high (score 2-3) T-cell infiltrates. In the extratumoral compartment, on the other hand, pNETs demonstrated a much higher degree of infiltration than small intestine with these 3 populations: 50% to 70% of pNETs demonstrated high infiltrates, as compared with only 4% to 19% of SINETs. Levels of FOXP3 T regulatory cell infiltration were low in both tumor subtypes.
Grade 3 Well-Differentiated NET
Our cohort included 4 pNET cases with a Ki-67 of more than 20%, though still well-differentiated by morphology. The characteristics of these tumors did not seem to differ significantly from their lower-grade counterparts: none of the tumor cells were positive for PD-L1, whereas cytoplasmic expression of PD-L2 was observed in 3 of the 4 cases. Low levels of stromal PD-1, PD-L1, and PD-L2 were also observed. Infiltrates of CD3, CD45RO, CD8, and FOXP3 T-cells followed a pattern similar to that seen in the lower-grade tumors.
Associations Between Mutational Profile, Immune Checkpoint Marker Expression, and T-Cell Infiltrate
We finally assessed whether the mutational profiles of the SINET and pNET in our cohort were associated with immune checkpoint marker expression and/or levels of T-cell infiltrates. Twenty-two SINET cases in our cohort had been previously sequenced for CDKN1B, the only gene reported to be recurrently mutated in SINET. 26 Of these 22 cases, 5 contained mutations in CDKN1B. We found no clear associations between the presence of CDKN1B mutations and expression of PD-1, PD-L1, PD-L2, or T-cell infiltrates. We evaluated 27 pNET cases from our cohort for mutations in MEN1, DAXX, ATRX, and mTOR pathway genes, which comprise most genes that have been previously reported as being mutated in pNET. 33, 34 Of these 27 cases, 17 were evaluable for mutations in all of the previously mentioned genes: mutations were observed in MEN1 9/17 (53%), ATRX 3/17 (18%), DAXX 8/ 17 (47%), TSC1 3/17 (18%), TSC2 2/17 (12%), PTEN 1/17 (6%), and PIK3CA 1/17 (6%). We found no clear association between the presence of these mutations, expression of checkpoint markers, or degree of T-cell infiltrates. We similarly did not identify clear associations between these variables and patient survival.
DISCUSSION
Our study provides an initial overview of immune checkpoint marker expression and T-cell immune response in well-differentiated SINET and pNET. We found that expression of PD-1 and PD-L1 in both tumor subtypes is uncommon but that both subtypes express high levels of PD-L2. T-Cell immune infiltrates were more prominent in pNET than in SINET, as were known mutations in general, although we did not observe clear correlations between immune infiltrates and mutations in specific genes.
Our observation that well-differentiated small intestine and pNETs express only low levels of PD-1 and PD-L1 builds on findings in a previous publication focused on well-differentiated foregut and hindgut NET, which also found low levels of expression of these markers. 22 We observed high levels of expression of PD-L2 in both pNET and SINET, using both immunohistochemical techniques and direct measurement of RNA expression. PD-L2, like PD-L1, binds to the PD-1 receptor although its function has been less well defined. Most studies to date have reported that PD-L2 has an inhibitory function on T-cell proliferation, analogous to the function of PD-L1. 7 PD-L1 and PD-L2 are both located at the same locus on ch9, and copy number gains and amplifications, as well as increased protein expression of both ligands, have been reported in Hodgkin lymphoma. 35 High levels of PD-L2 expression have also been reported in mediastinal large B-cell lymphoma and in esophageal adenocarcinoma. 36, 37 The expression of PD-L2 in NETs raises the possibility that use of PD-1 inhibitors (but not PD-L1) inhibitors may have a potential therapeutic benefit. However, our concurrent observation that PD-L2 expression was predominantly cytoplasmic rather than membranous raises questions regarding its potential therapeutic significance. Further studies are warranted to confirm the potential role of PD-L2 in NET.
T-cell immune infiltrates have been considered a general marker of effective immune response. A previous study evaluating T-cell infiltrates in patients with resected NETs found that the presence of a high CD3 + T-cell infiltrate, suggestive of a robust immune response, was associated with improved recurrence-free survival in patients with intermediate grade tumors, whereas the presence of high FOXP3 + T-cell infiltrates, suggestive of an immune suppressive environment, was associated with shorter survival in NET with liver metastases. 38 We did not observe clear associations between T-cell infiltrates and survival but did observe that the prevalence of FOXP3 + (T regulatory) cells was relatively low in both pNET and SINET, suggesting that T regulatory cells may not play a major role in suppressing an immune response in this disease. We further found that high levels of both intratumoral and extratumoral immune infiltrates, defined by staining with CD45RO (T memory), CD3 (general T-cell), and CD8 (cytotoxic T-cell) markers were present in subsets of both pancreatic and small bowel NET and were generally more common in pNET than in SINET.
T-cell infiltrates have been broadly associated with both mutational burden and response to immune checkpoint inhibitors. 17, 39 Our observation of higher T-cell infiltrates in pNET compared with SINET is consistent with fact that recurrent mutations are relatively uncommon in SINET; in a previous study, Infiltrates were assessed based on T-cell marker expression and in the intra and extratumoral compartments separately. Low and high level infiltrates were defined as infiltrates with scores of 0-1 or 2-3, respectively, as defined in the methods section. recurrent mutations in CDKN1B were observed in only 8% of tumors. 26 In contrast, pNETs have been shown to have a relatively high prevalence of mutations in MEN1, DAXX, and ATRX, with less common recurrent mutations in mTOR pathway genes. 33, 34 We did not, however, identify associations between T-cell infiltrates and mutations in specific genes. We similarly did not identify associations between immune checkpoint marker expression and tumoral mutational profiles.
In conclusion, both pNET and SINET are characterized by low PD-1 and PD-L1 expression. The significance of high cytoplasmic expression PD-L2 in NET cells warrants further investigation. Tumor-infiltrating T-cells were observed in both small intestine and pNET, with more prominent infiltrates observed in pNET. Our observations suggest the presence of a tumor-specific immune response in NETs that potentially could be harnessed with emerging immunotherapeutic strategies.
